Beyond Medicine, Inc. develops and commercialises RebelCell, a clinic-distributed skincare brand built around its proprietary MitoCyte complex and research into mitochondrial activity in skin ageing and recovery. Its current post-treatment formulations are designed for use after aesthetic procedures including energy-based treatments, microneedling, chemical peels and surgery. The company describes its products as Swiss-made and clinically tested, with intended effects on cellular energy, inflammatory biomarkers and oxidative stress; these are the issuer’s product claims, not assertions of an approved drug or proven treatment for disease. Its official terms identify Beyond Medicine, Inc. as the operator of RebelCell and the partner-clinic sales channel. Kidron Capital lists the company in its portfolio and names Maria Gajda Horowitz as a board member. This is distinct from the South African homeopathy business beyondmedicine.co.za and the Dutch Rebelcell battery manufacturer.
